Loss of GATA6-a transcription factor that controls which genes are turned on or off-can reprogram colorectal cancer cells ...

Loss of GATA6—a transcription factor that controls which genes are turned on or off—can reprogram colorectal cancer cells ...

Shares of Exelixis, Inc. EXEL were down 1.08% after the company announced disappointing results from the final analysis of ...

Researchers found that loss of GATA6 reprograms colorectal cancer cells into flexible, fetal-like states that can spread to ...

Exelixis’ next franchise in a drug, zanzalintinib, has hit a clinical setback, although at least two groups of analysts ...

Colorectal cancer is one of the most common types of tumor and is responsible for around 10% of cancer-related deaths worldwide. The tumor is particularly dangerous when it forms metastases—i.e.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver ...

Patients with pulmonary metastasis from primary colorectal carcinoma often undergo sublobar pulmonary metastasectomy. To prevent local cancer recurrence, it is important to ensure an appropriate ...

To establish an effective radiological risk stratification feature for metachronous metastasis of colon cancer. This retrospective, single-center study enrolled patients with stage II/III colon cancer ...

Cancer is a leading cause of death worldwide, and among all cancers, colorectal cancer ranks second in mortality, responsible for more than 900,000 deaths in 2020. In the U.S., rates of colorectal ...

High vitamin B12 near a colon cancer diagnosis tracked with faster spread and far shorter survival across more than 37,000 ...